Palvella Therapeutics (PVLA) Net Income towards Common Stockholders Growth (1y) (2014 - 2026)
Powered by 
Analysis
Palvella Therapeutics (PVLA) Net Income towards Common Stockholders Growth (1y) (2014 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 6.48% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -6.81% |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 92.37% |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.21% |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 151.28% |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 327.74% |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | -12.04% |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 95.87% |
| 10 | Palvella Therapeutics | 2.24 Bn | 1.93 Bn | - | -130.92% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -130.92% |
| Mar 31, 2026 | -92.63% |
| Dec 31, 2025 | -19.26% |
| Sep 30, 2025 | -62.79% |
| Jun 30, 2025 | -116.93% |
| Mar 31, 2025 | -199.82% |
| Dec 31, 2024 | -124.34% |
| Sep 30, 2024 | 38.10% |
| Jun 30, 2024 | -271.01% |
| Mar 31, 2024 | 81.98% |
| Dec 31, 2023 | 223.93% |
| Sep 30, 2023 | 5.61% |
| Jun 30, 2023 | 120.93% |
| Mar 31, 2023 | -103.14% |
| Dec 31, 2022 | -1.48% |
| Sep 30, 2022 | 37.25% |
| Jun 30, 2022 | 27.21% |
| Mar 31, 2022 | -47.55% |
| Dec 31, 2021 | 11.27% |
| Sep 30, 2021 | -46.85% |